Citations

Showing 10 of 108081 citations.

An Interview with Allan S Jaffe: A Life Researching Cardiac Biomarkers
Jaffe, Allan S. , Jaffe, Allan S.

Mayo Clinic

Biomarkers in Medicine | April 21, 2023 | Volume: 17 | Issue: 4 | Pages: 181-187

10.2217/bmm-2023-0180 | PMID 37083423 Get It

PC42. The Epidemiology of Postoperative Catastrophic Health Expenditure in The United States
Rae, Ali I. , Yang, Alan Z. , Gilder, Hannah E., Choudhary, Niteesh K., Dimick, Justin B. , Alsan, Marcella , Pusic, Andrea L. , Ranganathan, Kavitha , Ehsan, Anam Noor

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 21, 2023 | Volume: 11 | Issue: 4S | Pages: 51-51

10.1097/01.gox.0000934528.60906.33 Get It

D18. Risk of Breast Cancer-Related Lymphedema: Development and Validation of a Clinically-Relevant, Patient-facing Prediction Model
Rochlin, Danielle H. , McLaughlin, Sarah A. , Coriddi, Michelle , Mehrara, Babak J. , Barrio, Andrea V. , Zee, Kimberly J. Van , Dayan, Joseph H.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 21, 2023 | Volume: 11 | Issue: 4S | Pages: 70-71

10.1097/01.gox.0000934684.25197.89 Get It

PC37. The Effect of Local Exosomes, Stem Cells and Tacrolimus on Neurite Extension
Saffari, Tara Sara, Rademakers, Daan J., Saffari, Tiam M. , Shin, Alexander Y.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 21, 2023 | Volume: 11 | Issue: 4S | Pages: 48-48

10.1097/01.gox.0000934508.60378.fd Get It

JAK2 inhibitor treatment of anemia in myelofibrosis
Tefferi, Ayalew , Vannucchi, Alessandro M. , Vannucchi, Alessandro M

Mayo Clinic

American Journal of Hematology | April 21, 2023 | Volume: 98 | Issue: 7 | Pages: 995-997

10.1002/ajh.26934 | PMID 37084128 Get It

Tissue-resident memory T cell maintenance during antigen persistence requires both cognate antigen and interleukin-15
Tieu, Roger , Zeng, Qiang , Zhao, Daqiang , Feizi, Neda, Manandhar, Priyanka , Williams, Amanda , Popp, Benjamin , Wood, Michelle A. , Demetris, Anthony J. , Tso, J. Yun , Johnson, Aaron J. , Abou‐Daya, Khodor I. , Shlomchik, Warren D. , Lakkis, Fadi G. , Manandhar, Priyanka , Wood-Trageser, Michelle A , Demetris, Anthony J , Johnson, Aaron J. , Kane, Lawrence P , Abou-Daya, Khodor I , Shlomchik, Warren D , Oberbarnscheidt, Martin H , Lakkis, Fadi G , Zhang, Gang

Mayo Clinic

Science Immunology | April 21, 2023 | Volume: 8 | Issue: 82 | Pages: No page available

10.1126/sciimmunol.add8454 | PMID 37083450 Get It

Our understanding of tissue-resident memory T (T RM ) cell biology has been largely developed from acute infection models in which antigen is cleared and sterilizing immunity is achieved. Less is known about T RM cells in the context of chronic antigen persistence and inflammation. We investigated factors that underlie T RM maintenance in a kidney transplantation model in which T RM cells drive rejection. In contrast to acute infection, we found that T RM cells declined markedly in the absence of cognate antigen, antigen presentation, or antigen sensing by the T cells. Depletion of graft-infiltrating dendritic cells or interruption of antigen presentation after T RM cells were established was sufficient to disrupt T RM maintenance and reduce allograft pathology. Likewise, removal of IL-15 transpresentation or of the IL-15 receptor on T cells during T RM maintenance led to a decline in T RM cells, and IL-15 receptor blockade prevented chronic rejection. Therefore, antigen and IL-15 presented by dendritic cells play nonredundant key roles in CD8 T RM cell maintenance in settings of antigen persistence and inflammation. These findings provide insights that could lead to improved treatment of chronic transplant rejection and autoimmunity.
Surgical service and distance traveled drive patient preference for Care Hotel: a retrospective cohort study
Maniaci, Michael J. , Fazio, Jacey R., Maita, Karla C. , Love, Ellen A., Boyle, Venessa L., Paulson, Margaret R. , Maita, Karla , Paulson, Margaret R , Forte, Antonio Jorge , Maniaci, Michael J , Chadha, Ryan , Love, Ellen A, Heckman, Michael G. , Johnson, Patrick W. , Forte, Antonio J.

Mayo Clinic

Annals of Medicine & Surgery | April 21, 2023 | Volume: 85 | Issue: 5 | Pages: 1578-1583

10.1097/ms9.0000000000000704 | PMID 37229076 Get It

Background: Mayo Clinic’s Care Hotel is a virtual hybrid care model which allows postoperative patients to recover in a comfortable environment after a low-risk procedure. Hospitals need to understand the key patient factors that promote acceptance of the Care Hotel if they are to benefit from this innovative care model. This study aims to identify factors that can predict whether a patient will stay at Care Hotel. Materials and methods: This retrospective chart review of 1065 patients was conducted between 23 July 2020, and 31 December 2021. Variables examined included patient age, sex, race, ethnicity, Charlson comorbidity index, distance patient travelled to hospital, length of surgery, day of the week of surgery, and surgical service. Associations of patient and surgery characteristics with the primary outcome of staying at the Care Hotel were assessed using unadjusted and multivariable logistic regression models. Results: Of the 1065 patients who met criteria for admission to the Care Hotel during the study period, 717 (67.3%) chose to stay at the Care Hotel while 328 (32.7%) choose to be admitted to the hospital. In multivariable analysis, there was a significant association between surgical service and staying at the Care Hotel (P<0.001). Specifically, there was a higher likelihood of staying at the Care Hotel for patients from Neurosurgery [odds rato (OR)=1.86, P=0.004], Otorhinolaryngology (OR=2.70, P<0.001), and General Surgery (OR=2.75, P=0.002). Additionally, there was a higher likelihood of staying at the Care Hotel with distance travelled over 110 miles [OR (per each doubling)=1.10, P=0.007]. Conclusion: When developing a post-surgical care model for patients following outpatient procedures, the referring surgical service is a primary factor to consider in order to ensure patient acceptance, along with patient distance. This study can assist other healthcare organizations considering this model, as it provides guidance on which factors are most indicative of acceptance.
Association of d-dimer levels with in-hospital outcomes among COVID-19 positive patients: a developing country multicenter retrospective cohort
Tahir, Muhammad Junaid , Yasmin, Farah , Naeem, Unaiza , Najeeb, Hala , Kumar, Kamlesh, Arti, Majeed, Abdul , Wali, Agha, Sandhya, Sandhya , Shahab, Ramsha, Ahmed, Khabab Abbasher Hussien Mohamed , Hegazi, Moustafa , Abbasher Hussien Mohamed Ahmed, Khabab , Kumar, Rahul Robaish , Hegazi, Moustafa, Asghar, Muhammad Sohaib

Mayo Clinic

Annals of Medicine & Surgery | April 21, 2023 | Volume: 85 | Issue: 5 | Pages: 1527-1533

10.1097/ms9.0000000000000633 | PMID 37228954 Get It

Introduction D-dimer levels, which originate from the lysis of cross-linked fibrin, are serially measured during coronavirus disease 2019 illness to rule out hypercoagulability as well as a septic marker. Methods This multicenter retrospective study was carried out in two tertiary care hospitals in Karachi, Pakistan. The study included adult patients admitted with a laboratory-confirmed coronavirus disease 2019 infection, with at least one measured d-dimer within 24 h following admission. Discharged patients were compared with the mortality group for survival analysis. Results The study population of 813 patients had 68.5% males, with a median age of 57.0 years and 14.0 days of illness. The largest d-dimer elevation was between 0.51–2.00 mcg/ml (tertile 2) observed in 332 patients (40.8%), followed by 236 patients (29.2%) having values greater than 5.00 mcg/ml (tertile 4). Within 45 days of hospital stay, 230 patients (28.3%) died, with the majority in the ICU (53.9%). On multivariable logistic regression between d-dimer and mortality, the unadjusted (Model 1) had a higher d-dimer category (tertile 3 and tertile 4) associated with a higher risk of death (OR: 2.15; 95% CI: 1.02–4.54, P=0.044) and (OR: 4.74; 95% CI: 2.38–9.46, P<0.001). Adjustment for age, sex, and BMI (Model 2) yields only tertile 4 being significant (OR: 4.27; 95% CI: 2.06–8.86, P<0.001). Conclusion: Higher d-dimer levels were independently associated with a high risk of mortality. The added value of d-dimer in risk stratifying patients for mortality was not affected by invasive ventilation, ICU stays, length of hospital stays, or comorbidities.
Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials
Hallemeier, Christopher L. , Moughan, Jennifer, Haddock, Michael G. , Herskovic, Arnold, Minsky, Bruce D. , Suntharalingam, Mohan, Zeitzer, Kenneth L. , Garg, Madhur , Greenwald, Bruce D. , Komaki, Ritsuko , Puckett, Lindsay , Kim, Harold E., Lad, Thomas E. , Okawara, Gordon, Raben, Adam , Schefter, Tracey E., Barker, Jerry L. , Videtic, Gregory M.M. , Jacob, Rojymon , Winter, Kathryn, Crane, Christopher H. , Kim, Harold E , Hallemeier, Christopher Leigh , Kim, Hyun Jee , Lloyd, Shane , Bush, David A. , Meyer, Joshua E. , Falkson, Carla I.

Mayo Clinic

JAMA Network Open | April 21, 2023 | Volume: 6 | Issue: 4 | Pages: e238504

10.1001/jamanetworkopen.2023.8504 | PMID 37083668 Get It

Importance For many types of epithelial malignant neoplasms that are treated with definitive radiotherapy (RT), treatment prolongation and interruptions have an adverse effect on outcomes. Objective To analyze the association between RT duration and outcomes in patients with esophageal cancer who were treated with definitive chemoradiotherapy (CRT). Design, Setting, and Participants This study was an unplanned, post hoc secondary analysis of 3 prospective, multi-institutional phase 3 randomized clinical trials (Radiation Therapy Oncology Group [RTOG] 8501, RTOG 9405, and RTOG 0436) of the National Cancer Institute–sponsored NRG Oncology (formerly the National Surgical Adjuvant Breast and Bowel Project, RTOG, and Gynecologic Oncology Group). Enrolled patients with nonmetastatic esophageal cancer underwent definitive CRT in the trials between 1986 and 2013, with follow-up occurring through 2014. Data analyses were conducted between March 2022 to February 2023. Exposures Treatment groups in the trials used standard-dose RT (50 Gy) and concurrent chemotherapy. Main Outcomes and Measures The outcomes were local-regional failure (LRF), distant failure, disease-free survival (DFS), and overall survival (OS). Multivariable models were used to examine the associations between these outcomes and both RT duration and interruptions. Radiotherapy duration was analyzed as a dichotomized variable using an X-Tile software to choose a cut point and its median value as a cut point, as well as a continuous variable. Results The analysis included 509 patients (median [IQR] age, 64 [57-70] years; 418 males [82%]; and 376 White individuals [74%]). The median (IQR) follow-up was 4.01 (2.93-4.92) years for surviving patients. The median cut point of RT duration was 39 days or less in 271 patients (53%) vs more than 39 days in 238 patients (47%), and the X-Tile software cut point was 45 days or less in 446 patients (88%) vs more than 45 days in 63 patients (12%). Radiotherapy interruptions occurred in 207 patients (41%). Female (vs male) sex and other (vs White) race and ethnicity were associated with longer RT duration and RT interruptions. In the multivariable models, RT duration longer than 45 days was associated with inferior DFS (hazard ratio [HR], 1.34; 95% CI, 1.01-1.77; P = .04). The HR for OS was 1.33, but the results were not statistically significant (95% CI, 0.99-1.77; P = .05). Radiotherapy duration longer than 39 days (vs ≤39 days) was associated with a higher risk of LRF (HR, 1.32; 95% CI, 1.06-1.65; P = .01). As a continuous variable, RT duration (per 1 week increase) was associated with DFS failure (HR, 1.14; 95% CI, 1.01-1.28; P = .03). The HR for LRF 1.13, but the result was not statistically significant (95% CI, 0.99-1.28; P = .07). Conclusions and Relevance Results of this study indicated that in patients with esophageal cancer receiving definitive CRT, prolonged RT duration was associated with inferior outcomes; female patients and those with other (vs White) race and ethnicity were more likely to have longer RT duration and experience RT interruptions. Radiotherapy interruptions should be minimized to optimize outcomes.
Cohort study examining associations between ceramide levels and risk of multimorbidity among persons participating in the Mayo Clinic Biobank
Rocca, Walter A. , Sohn, Sunghwan , Weston, Susan A., McGree, Michaela E. , St Sauver, Jennifer L , Rocca, Walter A , Bielinski, Suzette , Sauver, Jennifer L. St. , LeBrasseur, Nathan K. , Olson, Janet E. , Bielinski, Suzette J. , Mielke, Michelle M.

Mayo Clinic

BMJ Open | April 21, 2023 | Volume: 13 | Issue: 4 | Pages: e069375

10.1136/bmjopen-2022-069375 | PMID 37085302 Get It

Objective Ceramides have been associated with several ageing-related conditions but have not been studied as a general biomarker of multimorbidity (MM). Therefore, we determined whether ceramide levels are associated with the rapid development of MM. Design Retrospective cohort study. Setting Mayo Clinic Biobank. Participants 1809 persons in the Mayo Clinic Biobank ≥65 years without MM at the time of enrolment, and with ceramide levels assayed from stored plasma. Primary outcome measure Persons were followed for a median of 5.7 years through their medical records to identify new diagnoses of 20 chronic conditions. The number of new conditions was divided by the person-years of follow-up to calculate the rate of accumulation of new chronic conditions. Results Higher levels of C18:0 and C20:0 were associated with a more rapid rate of accumulation of chronic conditions (C18:0 z score RR: 1.30, 95% CI: 1.10 to 1.53; C20:0 z score RR: 1.26, 95% CI: 1.07 to 1.49). Higher C18:0 and C20:0 levels were also associated with an increased risk of hypertension and coronary artery disease. Conclusions C18:0 and C20:0 were associated with an increased risk of cardiometabolic conditions. When combined with biomarkers specific to other diseases of ageing, these ceramides may be a useful component of a biomarker panel for predicting accelerated ageing.